LEVOFLOXACIN A POTENT ANTIBIOTIC - researchgate.net
Transcript of LEVOFLOXACIN A POTENT ANTIBIOTIC - researchgate.net
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/259707126
REVIEW ARTICLE LEVOFLOXACIN: A POTENT ANTIBIOTIC INTRODUCTION
Article · January 2011
CITATION
1READS
6,244
4 authors, including:
Some of the authors of this publication are also working on these related projects:
Liquid(Water)-solid(Benzoic acid) mass transfer in two phase mini-fluidized bed View project
Pediatric Infant Formula View project
Aa Aa
University Z
42 PUBLICATIONS 118 CITATIONS
SEE PROFILE
Iqbal A Shahnavi
University of Malakand
95 PUBLICATIONS 1,462 CITATIONS
SEE PROFILE
All content following this page was uploaded by Aa Aa on 15 January 2014.
The user has requested enhancement of the downloaded file.
1
REVIEW ARTICLE
LEVOFLOXACIN: A POTENT ANTIBIOTIC
Rahila Bano*, Adeel Arsalan, Iqbal Ahmad, Zufi Shad
ABSTRACT
Levofloxacin is a third generation fluoroquinolone antibacterial agent with a broad spectrum
activity against Gram-positive and Gram-negative bacteria and atypical pathogens. It shows its
bacteriocidal activity by inhibiting topoisomerase IV and DNA gyrase. Levofloxacin has shown
strong antibacterial activity against Staphylococcus species, Streptococcus pyogenes,
Streptococcus pneumoniae. Staphylococcus haemolyticus, Enterobacter species, Escherichia
coli, Salmonella species Klebsiella species Serratia species, Enterococcus species, Proteus.
Species, Pseudomonas aeruginosa, Haemophilus influenzae and Neisseria gonorrhoea.
Moreover, levofloxacin has showed antifungal activity against Chlamydia trachomatis. It is also
active against penicillin-resistant Streptococcus pneumoniae. It also possesses killing effect on
resistant mycobacteria like Mycobacterium tuberculosis and Mycobacterium leprae causing
tuberclosis and even Mycoplasma species of HIV infection. It is indicated in the treatment of
urinary tract infection, respiratory tract infection, biliary tract infection and other infection with
clinical efficacy of 80-92%.
*Corresponding author: [email protected]
Baqai Institute of Pharmaceutical Sciences
2
INTRODUCTION
Antibiotics are among the most frequently prescribed medications in modern medicin, they cure
disease by killing or inhibiting bacteria. The first antibiotic was penicillin, discovered
accidentally from a penicillium notatum.1 Today, over 100 different antibiotics are available to
doctors to cure minor discomforts as well as life- threatening infections.
Although antibiotics are useful in a wide variety of infections, it is important to realize that
antibiotics not only treat bacterial infections but also used in the prevention of infection.
Antibiotics were once considered as “wonder drugs”. Antibiotics are used for decades to
effectively treat a number of bacterial infections. Unfortunately, due to the overuse and misuse of
antibiotics, the resistant of bacteria may develop globally. The resistant is now become a fire
alarm to health care professionals.
History of Antibiotics
Pasteure and Joubert were among the first to recognize the potential of microbial products as
therpeutic agents in 1877.1 Penicillin becomes available for clinical use in 1941. Streptomycin,
chloramphenicol, and clarithromycin were identified towards the end of or soon after world war
II.1 Then after, numerous classes of antimicrobial agents have been discovered. Antibiotic are
effecftive against a number of microorganisms. They are used in the treatment of different
bacterial infections such as respiratory tract, gastrointestinal tract, urinary tract, skin and soft skin
tissue infections, nose and throat infections, meningitis, gonorrhea and dental abscess, septiemia
and pneumnia etc.2
Quinolones and Fluoroquinolones
With the increasing number of available quinolone antibiotics, prescribing these drugs has
become a challenge. Compared with older quinolones such as norfloxacin and ciprofloxacin, the
newer agents have an expanded antimicrobial spectrum and new indications. The most recently
released agents have significant antimicrobial activity against Gram-positive, Gram-negative,
atypical pathogens and anaerobes. The new classification of quinolone antibiotics by generation
3
can help family physicians prescribe these agents appropriately and evaluate new drugs as they
are introduced.3
The fluoroquinolones are broad-spectrum antibiotics with particular activity against Gram-
negative organisms, especially Pseudomonas aeruginosa. These agents are well absorbed when
given orally. Because tissue and fluid concentrations often exceed the serum drug concentration,
these antibiotics are particularly useful for certain infections, such as pneumonia.4-5
History and Chemistry of Quinolone
The original quinolone antibiotics included nalidixic acid, cinoxacin and oxolinic acid. The
addition of fluoride to the original quinolone antibiotic compounds yielded a new class of drugs,
the fluoroquinolones, which have a broader antimicrobial spectrum and improved
pharmacokinetic properties.6
Mode of Action
Physical studies have further defined interactions of quinolones with their principal target, DNA
gyrase. The binding of quinolones to the DNA gyrase-DNA complex suggests two possible
binding sites of differing affinities. Mutations in either the gyrase A gene (gyrA) or the gyrase B
gene (gyrB) that affect quinolones susceptibility also affect drug binding, with resistance
mutations causing decreased binding and hypersusceptibility mutations causing increased
binding.7 Regulation of expression of membrane efflux transporters may contribute to quinolone
susceptibility in both Gram-positive and Gram-negative bacteria. The substrate profile of the
nalidixic acid efflux transporter of bacteria correlates with the extent to which the activity of
quinolone substrates is affected by over expression of nalidixic acid. In addition, the Emr
transporter of Escherichia coli affects susceptibility to nalidixic acid, and the MexAB OprK
transport system of P. aeruginosa affects susceptibility to ciprofloxacin.2
The fluoroquinolones are bactericidal antibiotics that act by specifically targeting DNA gyrase.8
In contrast to amino glycosides and beta lactams, some fluoroquinolones are active against
dormant and replicating bacteria.9 Fluoroquinolones exhibit a post-antibiotic effect following
bacterial exposure to inhibitory concentrations. The antibacterial effect continues for
4
approximately two to three hours after bacteria are exposed to these drugs, despite sub-inhibitory
concentrations. The duration of the post-antibiotic effect may be increased with longer bacterial
drug exposure and higher drug concentrations.
Classification of Quinolone Antibiotics
First Generation
The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least
often used quinolones. Because minimal serum levels are achieved, use of these drugs has been
restricted to the treatment of uncomplicated urinary tract infections.
Second Generation
Second generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and
ofloxacin. These quinolones have increased Gram-negative activity, as well as some Gram-
positive and atypical pathogen coverage. Compared with first-generation drugs and considered as
a group, these agents have broader clinical applications in the treatment of complicated urinary
tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin
infections. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa.10-11
Because
of its good penetration into bone Ciprofloxacin and ofloxacin are the most widely used second-
generation quinolones because of their availability in oral and intravenous formulations.
Third Generation
The third generation quinolones currently include levofloxacin, gatifloxacin, moxifloxacin and
sparfloxacin. These agents are separated into a third class because of their expanded activity
against Gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant
Streptococcus pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and
Chlamydia pneumoniae.5, 10, 12
Although the third-generation quinolones retain broad Gram-
negative coverage. Because of their expanded antimicrobial spectrum, third-generation
quinolones are useful in the treatment of community-acquired pneumonia, acute sinusitis and
acute exacerbations of chronic bronchitis.
5
Fourth Generation
Trovafloxacin, currently the only member of the fourth-generation class, adds significant
antimicrobial activity against anaerobes while maintaining the Gram-positive and Gram-negative
activity of the third-generation quinolone.
LEVOFLOXACIN
Levofloxacin is the optical S- (-) isomer of ofloxacin which has been developed by the Daiichi
Seiyaku Pharmaceutical Co. Ltd, in Japan. Ofloxacin is a racemic mixture, but the S-isomer has
antibacterial activity 32- to 128-fold more potent than the R-isomer – hence most of the
antibacterial activity of ofloxacin is due to the S-isomer. Levofloxacin has been developed to
take advantage of this antibacterial potency while requiring only about half the usual dose of
ofloxacin to achieve similar efficacy, but potentially with an improved toxicity profile.13-17
Mechanism of Action
Levofloxacin is the L-isomer of the racemate, ofloxacin, and a quinolone antibacterial agent. The
antibacterial activity of ofloxacin resides primarily in the L-isomer. The mechanism of action of
levofloxacin and other quinolone antibacterials involves inhibition of DNA gyrase, an enzyme
required for DNA replication, transcription, repair and recombination. Levofloxacin has in vitro
activity against a wide range of Gram-negative and Gram-positive micro-organisms.
Levofloxacin is often bactericidal at concentrations equal to or slightly greater than inhibitory
concentrations.18-19
Antibacterial Activity
Levofloxacin is a broad-spectrum antibacterial agent against Gram-positive and Gram-negative
bacteria including anaerobes. Levofloxacin has shown strong antibacterial activities against
Staphylococcus species, Streptococcus pyogenes, Streptococcus pneumoniae. Staphylococcus
haemolyticus, Enterobacter species, Escherichia coli, Salmonella species Klebsiella species
Serratia species, Enterococcus species, Proteus. species and other glucose non fermentive Gram-
negative rod Pseudomonas aeruginosa, Haemophilus influenzae and Neisseria gonorrhoea.
More over levofloxacin has shows antibacterial activity against Chlamydia trachomatis.19-20
6
Gram-Negative Bacteria
Levofloxacin is about two-folds more active than ofloxacin and generally two to four fold less
active than ciprofloxacin against most Enterobacteriaceae and P.aeruginosa. The MIC90 of
levolfoxacin against P.aeruginosa is generally 4-8 µg per ml. Similary, levofloxacin is
comparable with, or one-or two dilutions inferior to ciprofloxacin in its activity against H.
influenzae, N. gonorrhoeae and Moraxella caterhalis, with MIC90 values of 0.015 -0.06 µg per
ml.21-24
Similar levofloxacin activity has been noted against Gram-negative pathogens isolated
from cancer patients-a clinical setting in which levofloxacin may have a future role.22
Levofloxacin has good activity against both Pasteurella species and Eikenella corrodens with
MIC90 values of 0.015 µg per ml.25
The MIC90 of levofloxacin against Legionella pneumophila is
0.125 µg per ml, compared with 0.25 µg per ml for ofloxacin.26
Levofloxacin is slightly more active against Bacteroides fragilis than ciprofloxacin with an
MIC90 2 µg per ml; but in general, levofloxacin can only be considered to have low activity
against anaerobes Fusobacterium species are resistant (MIC90 64µg per ml).21,27
Gram-Positive Bacteria
Levofloxacin is about two fold more active than ciprofloxacin against penicillin-susceptible and
resistant S. pneumoniea (MIC90 2µg per ml) and two to four fold more active against methicillin-
susceptible Staphlococcus aureus (MIC90 0.5µg per ml) Activity against methicillin-resistant
S.aureus (MRSA) is less impressive with MIC90 16µg per ml. concentrations of 1-2 µg per ml
inhibit 90% of Streptococci, while the MIC90 against Enterotoccus faecalis is generally no better
than 2µg per ml. Indeed, 28
found only 39% of vancomycin-susceptible and 11% vancomycin-
resistant strains of Enterococci were susceptible to <2 mg per ml levofloxacin. Levofloxacin has
variable activity against Listeria monocytogenes (MIC90 2-8 µg per ml) and is poorly active
against Corynebacterium jeikeium (MIC90 > 64 µg per ml).22-24, 29-31
Levofloxacin has variable activity against Gram-positive anaerobes, with MIC90 8µg per ml
against Peptostreptococcus species and broadly similar activity against Clostridium species.21, 25,
27
7
Mycobacteria
In vivo studies of Mycobacterium tuberculosis suggest that levofloxacin activity is comparable
with that produced by two-folds greater dosage of ofloxacin, although the MIC90 values for both
drugs are similar at 1 µg per ml. Sparfloxacin has better activity with MIC90 0.5µg per ml.32
Several workers have found similar findings in vitro.33-34
Rifampicin and isoniazid were more
active than levolfoxacin in a murine model of tuberculosis, but there was little difference in
activity between levofloxacin and ethambutol or pyrazinabide.35
Levofloxacin (MIC90 0.75 µg
per ml) has two fold greater bactericidal activity against Mycobacterium leprae then ofloxacin.36
Mycoplasma
Levofloxacin is active against Mycoplasma fermentans, the Mycoplasma species isolated in
patients with HIV infection, with MIC90 0.078 µg per ml.37
Pharmacokinetics
Absorption
Levofloxacin is rapidly and essentially completely absorbed after oral administration. Peak
plasma concentrations are usually attained one to two hours after oral dosing. The absolute
bioavailability of a 500 mg oral dose of levofloxacin is approximately 99%.2 Levofloxacin
pharmacokinetics is linear and predictable after single and multiple oral dosing regimens. Steady
state is reached with in 48 hours following a 500 mg once-daily regimen. The peak and through
plasma concentrations attained following multiple once-daily oral 500 mg regimens were
approximately 5.7 and 0.5 mcg/ml, respectively.38
Oral administration with food slightly prolongs the time to peak concentration by approximately
1 hour and slightly decreases the peak concentration by approximately 14%. Therefore
levofloxacin can be administered without regard to food. The plasma concentration profile of
levofloxacin after IV administration is similar and comparable in extent of exposure (AUC) to
that observed for levofloxacin tablets when equal doses (mg/ml) are administered. Therefore, the
oral and IV routes of administration can be considered interchangeable.39-41
Distribution
8
The mean volume of distribution of levofloxacin generally ranges from 89 to 112 L after single
and multiple 500 mg doses, indicating widespread distribution into body tissues. Penetration of
levofloxacin into blister fluid is rapid and extensive.2 Levofloxacin also penetrates well into lung
tissues. Lung tissue concentrations were generally two to five folds higher than plasma
concentrations and ranged from approximately 2.4 to 11.3 mcg/ml over a 24-hour period after a
single doseof 500mg oral dose.42-43
Levofloxacin is approximately 24 to 38% bound to serum
proteins across all species studied, as determined by the equilibrium dialysis method.
Levofloxacin is mainly bound to serum albumin in humans. Levofloxacin binding to serum
proteins is in dependent of the drugs concentration.44-48
Metabolism
Levofloxacin is stereochemically stable in plasma and urine and does not invert metabolically to
its enantiomer, D-ofloxacin.19
Levofloxacin undergoes limited metabolism in humans and is
primarily excreted as unchanged drug in urine. Following oral administration, approximately
87% of an administered dose was recovered as unchanged drug in urine within 48 hours.2
Excretion
Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma
elimination half-life of levofloxacin ranges from approximately six to eight hours following
single or multiple doses of levofloxacin give orally or intravenously. The mean apparent total
body clearance and renal clearance range from approximately 144 to 226 ml/min and 95 to 142
ml/min, respectively. Renal clearance in excess of the glomerular filtration rate suggests that
tubular secretion of levofloxacin occurs in addition to its glomerular filtration.18, 49-51
Concomitant administration of either cimetidine or probenecid results in approximately 24% and
35% reduction in the levofloxacin renal clearance, respectively, indicating that secretion of
levofloxacin occurs in the renal proximal tubule. No levofloxacin crystals were found in any of
the urine samples freshly collected from subjects receiving levofloxacin.2
Therapeutic Uses
Therapeutically it is used for urinay tract infection, sinusitis, and chronic bronchitis.
Uncomplicated mild to moderate infection of skin and skin structure including abscesses,
cellulitis and wound infection, acute mild to moderate pyelonephritis against a variety of aerobic
9
Gram-positive and Gram-negative bacteria, including Tubercle bacilli, P. aeruginosa and
Enterococus faecalis are only moderately susceptible. Levofloxacin is also administered
topically as 0.5% eye drop for the treatment of bacterial conjunctivitis.2, 19
Urinary Tract Infections and Prostatitis
Various Japanese studies of levofloxacin 100-200 mg thrice daily for 3-14 days suggest rates of
clinical efficacy of 85-100% in the treatment of uncomplicated and complicated urinary tract
infections.52
Found levofloxacin in 250mg daily for 10 days to have similar efficacy of either
ciprofloxacin 500 mg twice daily for 10 days, or lomefloxacin 400 mg daily for 14 days, in the
treatment of acute pyelonephritis.
Levofloxacin in the treatment of acute and chronic prostatitis, epidiymitis and gonococcal and
chlamydial urethritis.16
in a small open study of 23 patients with acute epididymitis treated with
levofloxacin 100 mg two or three times daily for 14 days, overall clinical efficacy was 100%.53
A
5-day course of 300mg per day levofloxacin was effective in a small study of gonococcal
urethritis.54
Respiratory Tract Infections
Levofloxacin to be effective in the treatment of respiratory tract infections when used in doses
ranging from 200 mg once daily to 200mg thrice daily.16
In one study, treatment of 12 patients
with various lower respiratory tract infections with levofloxacin 200mg once-daily for 7-14 days
resulted in 100% efficacy.17
Other authors using various regimens, including 100-200mg thrice-
daily, have found less satisfactory results with approximately only 50% patients classified as
having a 'good' or 'excellent' clinical outcome. As might be expected, knowing the in vitro
activity of levofloxacin, the rate of P. aeruginosa eradication was low in the 300 mg per day
group, but approached 75% in patients receiving 200 mg thrice daily.55-57
In one of the largest
studies reported, 58
examined the efficacy of either 300 or 600 mg per day in 87 patients who
were managed either as outpatients (300 mg per day for 3 days) or as inpatients (200 mg thrice-
daily for 7 days). Eradication of responsible pathogens was noted in 80% cases by day 7, and
among patients with, pneumonia, clinical efficacy was noted in about 89% cases. A 7- to l4-day
course of levofloxacin 500 mg once-daily appears to be as effective as coftriaxone (l-2 g per
10
day)/cefuroxime (500 mg twice-daily) for community-acquired pneumonia, and cefaclor 250 mg
twice-daily for acute exacerbations of chronic bronchitis.59-60
Biliary Tract Infections
Among 11 patients with biliary tract infections (six cholecystitis; three cholangitis;
cholecystocholangitis and liver abscess) treated with levofloxacin l00-200mg thrice daily for 3-
14 days, clinical outcome was good in eight patients (73%) and in the remainder.61
Other Infections
Non-comparative studies of levofloxacin 100mg thrice-daily for soft tissue and skin infections,
obstetric and gynecological infections and ear, nose and throat infections (occasionally requiring
200mg thrice-daily) have demonstrated overall clinical efficacy in about 80-92% cases.16
Levofloxacin 500 mg once daily for 7 days appears to have efficacy comparable with
ciprofloxacin 500mg twice-daily for 7 days in the treatment of skin and skin structure infections,
with reported rates of cure/improvement in 96.1 % versus 93.5% cases, respectively.62
In one Japanese study of 22 patients with obstetric and gynecological infections, the clinical
efficacy of levofloxacin 200-600mg daily for 3-14 days was 95%.63
In a study of 114 patients
with bacterial enteritis levofloxacin 200-300mg per day for 3-5 days was associated with clinical
cure rate of 97% .16
Toxicity
Doses of 200-600 mg levofloxacin per day appear to be well tolerated with side effects largely
consisting of those noted with all fluorquinolones, such as55, 64-65
Shock: Since shock symptoms may rarely occur, observe patients carefully .if any abnormalities
are observed, discontinue the medication and take appropriate measure.
Hypersensitivity: Anaphylactoid symptoms (erythema, chills, dyspnea), edema, urticaria,
feeling of warmth or photosensitivity may rarely occur and rash or pruritus may infrequently
occur. In the event of such symptoms, discontinue the medication.
11
Dermatological: It has been reported that ofloxacin may rarely cause lyell syndrome or stevens
Johnson syndrome.
Psychoneurological: Convulsion, tremor or numbness may rarely occur, and insomnia,
dizziness or headache may infrequently occur.
Renal: An increase in BUN may infrequently occur it has been reported that ofloxacin may
rarely cause acute renal failure.
Hepatic: An increase in SGOT, SGPT, Alkaline phosphatase, y-GT or total biliribin may
infrequently occur.
Hematologic: A decrease in leukocytes, erythrocytes, hemoglobin or homatocrit or an increase
in eosinophils may infrequently occur. Observe patient carefully, and if any abnormality is
observed, discontinue the medication.
Gastrointestinal: Nausea, vomiting, abdominal discomfort, diarrhea, anorexia, abdominal pain
or enlarged feeling of abdomen may infrequently occur. Since it has been reported that ofloxacin
may rarely cause severe colitis, with blood in the stool, such as pseudomembranous colitis, in the
event of abdominal pain or frequent diarrhea take appropriate measures, including
discontinuation of the medication.
Mascular: Since rhabdomyolysis with rapid deterioration of renal function characterized by
myalgia, weakness, increase in CPK or myoglobin in blood or urine may occur, patient should be
cautioned.
Drug Interactions
Since it has been reported that other quinolones used in combination with non steroidal anti-
inflammatory drugs of phenylacetic/ propionic acid derivatives, such as fenbufen, may rarely
cause convulsions, this product should be administered carefully.66
Antacids containing aluminium or magnesium and drugs containing iron may interfere with the
absorption of levofloxacin resulting in attenuation of the efficacy of levofloxacin. These agents
should be taken atleast two hours before or two hours after levofloxacin administration.2
12
Mode of Administration and Dosage
Oral Administration
The optimal dosage of levofloxacin for various patient populations has yet to be determined, but
most Japanese studies have used 100 mg thrice-daily (occasionally 200 mg thrice-daily) for the
treatment of a variety of infections, including respiratory, skin, biliary genitourinary,
obstetric/gyneocology and eye infections. The usual duration of treatment is single-dose therapy
for women with uncomplicated cystitis, 3-5 days for other urinary tract sepsis or gonococcal
urethritis and 7-14 days therapy for most other indications except for prostatitis, when longer
courses may be needed.16
Patients with Renal Failure
Since levofloxacin is mainly excreted unchanged in the urine. Serum levels are sensitive to
changes in renal function. Thus, dosage reduction is required in patients with renal impairment.
In Japanese patients, doses are reduced as follows; glomerular filtration rate (GFR) 40-70 ml per
min, 100 mg twice-daily; GFR 20-40 ml per min, 100mg daily; GFR <20 ml per min, 100mg
every 48 hours.16, 67
No information is available regarding the need for any dosage adjustment in
the elderly or in patients with hepatic failure.
CONCLUSIONS
Levofloxacin is a broad-spectrum antibiotic possess activity against Gram-positive and Gram-
negative and atypical microbes. Due to its lethal action on microorganisms, it has been widely
prescribed in respiratory tract infections, biliary tract infections and urinary tract infections with
clinical efficacy of 80-92%. It shows its bactericidal action on atypical pathogens like
Mycobacteria species and Mycoplasma species. It also possesses its action on resistant bacteria
like penicillin-resistant S. pneumoniae, Salmonella species Pseudomonas aeruginosa,
Haemophilus influenzae. Levofloxacin is well tolerated, and is associated with minimum side
effects.
REFERENCES
13
1. Fleming A (1929). On the antibacterial action of cultures of a penicillium with specifical
reference to their use in the isolation of B.influenzae. Brit. J Exp Path 10: 226; quoted by
Welch (1954).
2. Alfred Goodman Gilman, Louis S.Goodman, Theodore W.Rall, Ferid Murad. Goodman
and Gilman’s the pharmacological basis of therapeutic” 7th
edition, 1985. Macmillan
publishing company
3. Ambrose PG, Owens RC, Quintiliani R, Nightingale CH. New generations of quinolones:
with particular attension to levofloxacin”. Conn Med 1997; 61:269-72.
4. Garey KW, Amsden GW. “Trovafloxacin: an overview”. Pharmacotherpy 1999;19:21-
34.
5. Stein, GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin
Infect Dis. 1996; 23(1): S19-24.
6. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev.
1989; 2:378-424.
7. Hooper DC, Wolfson JS. “Mechanisms of quinolone action and bacterial killing. In
Quinolone Antimicrobial Agents 2nd
edn, 1993. Hooper DC, Wolfson JS, eds, p. 97.
Washington, DC: American Society of Microbiology.
8. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherpy 1993; 13:4-17S.
9. Fitton A. The quinolones. An overview of their pharmacology. Clin Pharmacokinet.
1992; 22(1): 1-11.
10. “Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther. 2000;
42:15-7.
11. Stein GE, Ensberg M. Use of newer fluoroquinolone in the elderly. Clin Geriatr. 1989;
6(8): 53-8.
14
12. Stein GE, Havlichek DH. Newer oral antimicrobials for resistant respiratory tract
pathogens. Which show the most promise? Postgrad Med. 1998; 103(6): 67-70:74-76.
13. Une T, Fujimoto T, Sato K, Osada Y. Invitro activity of Dr-3355, an optically active
ofloxacin. Antimicrob Ag Chemother. 1988; 32:1336.
14. Tanaka K, Iwamoto M, Maesaki S, Koga H, Kohno S, Hara K, Sugawara K, Kaku M,
Kusano S, Sakito O. Laboratory and clinical studies on levofloxacin. Jpn J Antibiot.1992;
45(5): 548-56.
15. Inage F, Kato M, Yoshida M, Akahane K, Takayama S.. Lack of nephrotoxic effects of
new quinolone antibacterial agent levofloxacin in rabbits. Arzneiymittelforschung. 1992;
43: 395.
16. Davis R, Bryson HM. Levofloxacin A review of its antibacterial activity,
pharmacokinetic and therapeutic efficacy. Drugs 1994; 47:677.
17. Nakamori Y, Miyashita Y, Nakatani I, Nakata K. Levofloxacin: penetration into sputum
and once daily treatment of respiratory tract infections. Drugs 1995; 49(2): 418.
18. Johnson RW. Levofloxacin Injection (Levaquin).U.S. Food and Drug Administration.
Center for Drug Evaluation and Research. 1996. Application number 020635.
19. U.S. Food and Drug Administration. Levaquin Prescribing Information. 2008
20. Croom KF, Goa KL.Levofloxacin: A review of its use in the treatment of bacterial
infections in the United States. Drugs, 2003; 63(24): 2769-2802.
21. Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, Rosenthale ME. In
vitro and in vivo antibacterial activities of levofloxacin (1-ofloxacin), an optically active
ofloxacin. Antimicrob Ag Chemother. 1992; 36:860.
22. Dholakia N, Rolston KV, Ho DH, B LeBlanc B, and Bodey GP. Susceptibilities of
bacterial isolates from patient with cancer to levofloxacin and other quinolones.
Antimicrob Ag Chemother. 1994; 38: 848.
15
23. Yamane N, Jones RN, Frei R, Hoban DJ, Pignatari AC, Marco F.. Levoloxacin in vitro
activity result from and international comparative study with ofloxcin and ciprofloxacin.
J Chemother. 1994; 6:83.
24. Soussy CJ, Cluzel M, Ploy MC, Kitzis MD, Morel C, Bryskier A, Courvalin P. In-vitro
antibacterial activity of levofloxacin against hospital isolates: a multicentre study. J
Antimicrob Chemother. 1999 Jun;43 Suppl C:43-50..
25. Goldstein EJ, Nesbit CA, Citron DM. Comparative in vitro activities of azithromycin,
Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against
194 aerobic and anaerobic bite wound isolates. Antimicrob Ag Chemother. 1995; 39:
1097
26. Baltch AL, Smith RP, Ritz W. Inhibitory and bactericidal activities of levofloxacin,
ofloxacin, erythromycin, and rifampin used singly and incombination against Legionella
pneumophila. Antimicrob Ag Chemother. 1995; 39:1661.
27. Appelbaum Pc. Quinolone activity against anaerobes microbiological aspect. Drugs
1995; 19 (suppl 2): 76.
28. Hayden MK, Matushek MG, Trenholme GM. Comparison of the in vitro activity of
levofloxacin and other antimicrobial agents against vancomycin-susceptible and
vancomycin-resistant Enterococcus species”. Diagn Microbiol Infect Dis. 1995; 22(4):
349-352.
29. Cherubin CE, Stratton CW. Assessment of bacteriological activity of sparfloxacin,
ofloxacin, levofloxacin and other fluoroquinolones compared with selected agent of
proven efficacy against Listeria monocytogenes. Diagn Microbial Infect Dis. 1994; 20:
21.
30. Parkuch GA, Jacobs MR, Appelbaum PC. Activity of CP99, 219 compared with DU-
.6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin
and grepafloxacin against penicillin susceptible and-resistant pneumococci. J Antimicrob
Chempther. 1995; 35: 230.
16
31. Punckuch GA, Jacobs MR, Appelbaum PC. Activity of DU-6859a, ciprofloxacin,
ofloxacin, levofloxacin, sparfloxacin' and OPC-17116 against 112 penicillin-susceptible
and resistant pneumococci. Drugs 1995; 49 (2): 235.
32. Ji B, Lounis N, Truffot-Pemot C, Grnsset J. In vitro and in vivo activities of levofloxacin
against Mycobacterium tuberculosis. Antimicrob Ag Chemother. 1995; 39: 1341.
33. Mor N, Vanderkolk J, Heifets L. In vitro and in human macrophages inhibitory and
bactericidal activities' of levofloxacin against Mycobacterium tuberculosis. Antimicrob
Ag Chemother. 1994; 38: 1161-1164.
34. Yew WW, Piddock LJ, Li MS, Lyon D, Chan CY, Cheng AF. In vitro activity of
quinolones and macrolides against mycobacteria”. J Antimicrob Chemother. 1994; 34:
343-351.
35. Klemens SP, Sharpe CA, Rogge MC, Cynamon MH. Activity of levofloxacin in a murine
model of tuberculosis. Antimicrob Ag Chemother. 1994; 38: 1476-1479.
36. Dhople Am, Ibanez MA. In vitro activity of levofloxacin, singly and in combination with
rifampicin analogs, against Mycobacterium leprae. Antimicrob Ag Chemother 1995; 39;
2116-2119.
37. Hayes MM, Foo HH, Kotain H, Wear DJ, Lo SC. In vitro antibiotic susceptibility testing
of different strains of Mycoplasma fermentans isolated from a variety of sources.
Antimicrob Ag Chemother. 1993; 37:2500-2503.
38. Chien SG, Rogge MC, Gisclon LG. Pharmacokinetic profile of levofloxacin following
once-daily 500-milligram oral or intravenous doses”. Antimicrob Agents Chemother.
1997; 41: 2256-2260.
39. Trampuz A, Wenk M, Rajacic Z, Zimmerli W. Pharmacokinetics and pharmacodynamics
of levofloxacin against Streptococcus pneumoniae and Streptococcus aureus in human
skin blister fluid. Antimicrob Agents Chemother 2000; 44(5): 1352-1355.
17
40. Amsden GH, Graci DM, Cabelus LJ, Hejmanowski LG. A randomized crossover design
study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal
infections. Chest. 1999; 116: 115-119.
41. Chien SC, Wong FA, Fowler CL (1998). “Double-blind evaluation of the safety and
pharmacokinetics of multiple oral once daily 750-milligram and 1-gram doses of
levofloxacin in healthy volunteers. Antimicrob Agents Chemother. 1998; 42: 885-888.
42. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet.
1997; 32: 101-119.
43. Langtry HD, Lamb HM. Levofloxacin: its use in infections of the respiratory tract, skin
soft tissues and urinary tract. Drugs 1998; 56(3): 487-515.
44. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new
fluoroquinolones. Focus on respiratory infections. Curr Opin Pharmacol. 2001; (5): 459-
463.
45. Rodvold KA, Danziiger LH, Gotfried MH. Steady-state plasma and bronchoplumonary
concentrations of intravenous levofloxacin and azithromycin in healthy adults.
Antimicrob Agents Chemother. 2003; 47(8): 2450-2457.
46. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary
concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001;
119: 1114-1122.
47. Nakamori Y, Tsuboi E, Narui K. Sputum penetratration of levofloxacin and its clinical
efficacy in patient with chronic lower respiratory tract infections. Jpn J Antibiot. 1992;
45: 539-547.
48. Nagai H, Yamasaki T, Masuda M. Penetration of levofloxacin in to bronchoalveolar
lavage fluid. Drugs. 1993; 45(3): 259.
18
49. Mollinaro M, Villani P, Regazzi MB, Rondanelli R, Doveri G. Pharmacokinetics of
ofloxacin in elderly patients and in healthy young subjects. Eur J Clin Pharmacol. 1992;
43: 105-107.
50. Lubasch A, Keller I, Borner K. Comparative pharmacokinetics of ciprofloxacin,
gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral
administration in healthy volunteers. Antimicrob Agents Chemother. 2000; 44: 2600-
2603.
51. Okazaki O, Kojima C, Hakusui H. Enantioselective disposition of ofloxacin in human.
Antimicrob Agents Chemother. 1991; 35(10): 2106-2109.
52. Richard GA, Klimberg IN, Fowler CL, Callery-D'Amico S, Kim SS. Levofloxacin versus
ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology. 1998 Jul;52(1):51-
55.
53. Saito I, Suzuki A, Saiko Y, Yokozawa M, Ono K. Acute nongonococcal epididymitis-
pharmacological and therapeutic aspects of levofloxacin. Hinyokika Kiyo 1992; 38
(5):623-628.
54. Osato K, Katsukawa C, Makino M. Treatment of gonococcal urethritis. Jpn J Antibiot.
1991; 44: 1206.
55. Kawai T . Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of
bacterial lower respiratory tract infections. Drugs. 1995; 49 (2): 416-417.
56. Odagiri S. Levofloxacin in patients with severe respiratory tract infection. Drugs 1995;
49 (2): 426-427.
57. Shishido H, Furukawa K, Nagai H Kawakami K, Kono H. Oral levofloxacin 600 mg and
300 mg daily doses in difficult-to-treat respiratory infections. Drugs. 1995; 49 (2): 433-
435.
19
58. Sato A, Ogawa H, Iwata M, Ono T, Yasuda K, Nagayama M, Shirai T, Shirai M, Ida
M, Suda T. Clinical efficacy of levofloxacin in elderly patients with respiratory tract
infections. Drugs 1995; 49 (2): 428-429.
59. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. A
multicenter, randomized study comparing the efficacy and safety of intravenous and/or
oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with
community-acquired pneumonia. Antimicrob Agents Chemother. 1997; 41(9):1965-1972.
60. Habib MP, Gentry LO, Rodriguez-Gomez G. Multicenter randomized study comparing
the efficacy and safety f oral levofloxacin vs. cefaclor in the treatment of acute bacterial
exacerbations of chronic bronchitis. Infect Dis Clin Pract. 1998; 7:101-109.
61. Tanimura H, Ohnishi H. Okatnura T Uenishi M, Ichimiya G, Kobayashi Y, Aoki Y, Oka
S, Yamamoto S, Shimada K. Chemotherapy of Biliary tract infections (XXXVII).
Excretion into bile and gall bladder tissue levels of levofloxacin and it clinical effect in
biliary tract infection. Jpn J Antibiot. 1992; 45: 557-568.
62. Nicodemo AC, Robledo JA, Jasovich A, Neto W. A multicenter, I randomized study
comparing the efficacy and safety of oral levofloxacin vs. ciprofloxacin in the treatment
of skin and skin structure infections Int J Clin Pract. 1998; 52(2):69-74.
63. Cho N, Araki H, Kimura T Shimizu A, Ichikawa K, Fukunaga K, Kunii K.
Pharmacokinetic and clinical evaluation of levofloxacin in obstetrics and gynecology.
Jpn J Antibiot. 1992; 45: 270-284.
64. Wagai N, Yoshida M, Takayamas S. Phototoxic potential of the new quinolone
antibacterial agent levofloxacin in mice. Arzneimittelforschung 1992; 42: 404-405.
65. Tanaka M, Kurata T, Fujisawa C Y Ohshima, H Aoki, O Okazaki, and H Hakusui.
Mechanistic study of inhibition of levofloxacin absobption by aluminium hydroxide.
Antimicrob Ag Chemother. 1993; 37;2173-2178.
20
66. Shiba K, Sakai O, Shimada J. Effects of antacids, ferrous sulfate and ranitidine on
absorption of DR-3355 in humans. Antimicrob Agents Chemother 1992; 36(10): 2270-
2274.
67. Saito A, Oguchi K, Harada Y. Pharmacokinetics of levofloxacin in patients with impaired
renal function. Chemother.1992; 40 (3): 188-195.
View publication statsView publication stats